NetworkNewsBreaks – Chiasma, Inc. (NASDAQ: CHMA) Closes $34.5M Offering Including Full Exercise of Underwriters’ Option
Chiasma (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, recently announced the closing of its underwritten public offering of 7,263,158 shares of its common stock at a price to the public of $4.75 each. The shares include 947,368 additional shares of common stock that were sold pursuant to the over-allotment option granted by the company to the underwriters, which was exercised in full. Chiasma received total gross proceeds of approximately $34.5 million, which the company intends to use primarily toward development costs, including the conduct of its ongoing phase…







